Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 30Active not recruiting 5Unknown 4Recruiting 3Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 508Uterine Cervical Neoplasms 361Endometrial Neoplasms 305Breast Neoplasms 130Colorectal Neoplasms 112Neoplasms 98Fallopian Tube Neoplasms 90Carcinoma, Non-Small-Cell Lung 87Stomach Neoplasms 83Pancreatic Neoplasms 79Lung Neoplasms 72Melanoma 68Prostatic Neoplasms 67Carcinoma, Ovarian Epithelial 65Neoplasm Metastasis 63Triple Negative Breast Neoplasms 51Vulvar Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Head and Neck Neoplasms 45Esophageal Neoplasms 43Uterine Neoplasms 40Peritoneal Neoplasms 40Urinary Bladder Neoplasms 38Carcinoma, Hepatocellular 35Carcinoma, Renal Cell 34Uterine Cervical Dysplasia 31Sarcoma 31Papillomavirus Infections 31Colonic Neoplasms 31Recurrence 29

Interventions

Vaccines, Synthetic 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Condylomata Acuminata × Gynecologic × Clear all
NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
8,000 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
1,348 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05371353 2024-04-17

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Shanghai Bovax Biotechnology Co., Ltd.

Recruiting
600 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡